Actuate Therapeutics (ACTU) Competitors $7.11 -0.28 (-3.79%) Closing price 04:00 PM EasternExtended Trading$7.12 +0.01 (+0.21%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ACTU vs. OPT, COGT, BCAX, IMNM, VALN, MRVI, DNTH, ORGO, GHRS, and ALMSShould you be buying Actuate Therapeutics stock or one of its competitors? The main competitors of Actuate Therapeutics include Opthea (OPT), Cogent Biosciences (COGT), Bicara Therapeutics (BCAX), Immunome (IMNM), Valneva (VALN), Maravai LifeSciences (MRVI), Dianthus Therapeutics (DNTH), Organogenesis (ORGO), GH Research (GHRS), and Alumis (ALMS). These companies are all part of the "pharmaceutical products" industry. Actuate Therapeutics vs. Opthea Cogent Biosciences Bicara Therapeutics Immunome Valneva Maravai LifeSciences Dianthus Therapeutics Organogenesis GH Research Alumis Opthea (NASDAQ:OPT) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations, community ranking and profitability. Which has stronger valuation & earnings, OPT or ACTU? Actuate Therapeutics has lower revenue, but higher earnings than Opthea. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpthea$87.67K5,986.77-$220.24MN/AN/AActuate TherapeuticsN/AN/A-$24.75MN/AN/A Does the media refer more to OPT or ACTU? In the previous week, Opthea had 4 more articles in the media than Actuate Therapeutics. MarketBeat recorded 5 mentions for Opthea and 1 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 0.94 beat Opthea's score of 0.47 indicating that Actuate Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Opthea Neutral Actuate Therapeutics Positive Do institutionals & insiders hold more shares of OPT or ACTU? 56.0% of Opthea shares are held by institutional investors. 3.2% of Opthea shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is OPT or ACTU more profitable? Company Net Margins Return on Equity Return on Assets OptheaN/A N/A N/A Actuate Therapeutics N/A N/A N/A Do analysts recommend OPT or ACTU? Opthea currently has a consensus target price of $1.33, suggesting a potential downside of 60.90%. Actuate Therapeutics has a consensus target price of $20.00, suggesting a potential upside of 181.29%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Actuate Therapeutics is more favorable than Opthea.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Opthea 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.17Actuate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor OPT or ACTU? Opthea received 18 more outperform votes than Actuate Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Actuate Therapeutics an outperform vote while only 48.72% of users gave Opthea an outperform vote. CompanyUnderperformOutperformOptheaOutperform Votes1948.72% Underperform Votes2051.28% Actuate TherapeuticsOutperform Votes1100.00% Underperform VotesNo Votes SummaryOpthea and Actuate Therapeutics tied by winning 6 of the 12 factors compared between the two stocks. Remove Ads Get Actuate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACTU and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACTU vs. The Competition Export to ExcelMetricActuate TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$138.87M$6.08B$5.17B$7.37BDividend YieldN/A3.01%5.35%4.25%P/E RatioN/A6.5021.7617.55Price / SalesN/A203.67351.7989.68Price / CashN/A65.6738.1534.64Price / BookN/A5.456.163.81Net Income-$24.75M$141.10M$3.19B$247.05M7 Day Performance-1.52%-3.35%-3.87%-3.50%1 Month Performance-2.34%-13.17%-2.66%-8.42%1 Year PerformanceN/A-19.80%3.36%-6.46% Actuate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACTUActuate TherapeuticsN/A$7.11-3.8%$20.00+181.3%N/A$138.87MN/A0.0010High Trading VolumeOPTOpthea0.7925 of 5 stars$3.41+7.2%$1.33-60.9%-16.6%$524.84M$87,666.000.008Gap UpCOGTCogent Biosciences1.9275 of 5 stars$4.58-4.0%$14.43+215.0%-36.2%$521.43MN/A-1.8580News CoverageGap DownHigh Trading VolumeBCAXBicara TherapeuticsN/A$9.51-10.0%$36.50+283.8%N/A$518.51MN/A0.0032Analyst ForecastAnalyst RevisionGap DownIMNMImmunome2.496 of 5 stars$5.88-0.8%$25.14+327.6%-69.7%$511.27M$9.04M-0.7340Gap DownVALNValneva1.6082 of 5 stars$6.24+4.3%$16.00+156.4%-16.4%$507.07M$169.58M-48.00700Analyst ForecastMRVIMaravai LifeSciences4.4587 of 5 stars$1.99+2.6%$7.31+267.1%-77.2%$506.13M$259.19M-1.21610Gap DownDNTHDianthus Therapeutics1.4411 of 5 stars$15.61-3.2%$54.33+248.1%-32.3%$501.47M$6.24M-6.2480Positive NewsGap DownORGOOrganogenesis3.9506 of 5 stars$3.89+0.5%$5.50+41.4%+39.7%$493.36M$482.04M-64.83950Gap DownGHRSGH Research2.6438 of 5 stars$9.32-7.6%$30.86+231.1%-17.9%$484.90MN/A-11.8010Gap DownHigh Trading VolumeALMSAlumis2.3732 of 5 stars$10.07+0.2%$26.00+158.2%N/A$475.53MN/A0.00N/AGap DownHigh Trading Volume Remove Ads Related Companies and Tools Related Companies OPT Competitors COGT Competitors BCAX Competitors IMNM Competitors VALN Competitors MRVI Competitors DNTH Competitors ORGO Competitors GHRS Competitors ALMS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACTU) was last updated on 4/10/2025 by MarketBeat.com Staff From Our PartnersTrump’s policies mean HUGE income for investorsThanks to a Trump win… Investors have a HUGE opportunity at new income. The floodgates for U.S. oil prod...The Oxford Club | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredThis almost killed Elon Musk (chilling details emerge)Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actuate Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Actuate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ACTU Stock Free ACTU Stock Alerts